Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441189 | 0.91 | KMT2A (0.43) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4791304 | 0.85 | KMT2A (0.43) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6948326 | 0.84 | KMT2A (0.42) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6948325 | 0.84 | KMT2A (0.42) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6948329 | 0.84 | KMT2A (0.42) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL12426672 | 0.78 | KMT2A (0.45) | KMT2AMAPK1 | |
| SCHEMBL12426674 | 0.78 | KMT2A (0.45) | KMT2AMAPK1 | |
| SCHEMBL2182258 | 0.78 | NAAA (0.46) | KMT2AL3MBTL1NAAACTSKSCN9A | |
| SCHEMBL2183100 | 0.77 | KDM1A (0.41) | KMT2ANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL14274003 | 0.77 | KMT2A (0.44) | KMT2ACCR5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | KMT2A 1856/4885NFKB1 1565/4885NFKB2 2548/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | KMT2A 2369/4885NFKB1 362/4885NFKB2 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.